Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report

Cancer research · Diffuse large B-cell lymphoma

The bispecific antibody glofitamab induced a durable partial response in a patient with primary refractory DLBCL/HGBL‑MYC/BCL2 transformed from follicular lymphoma, suggesting its use as salvage therapy.

Diffuse large B‑cell lymphoma/high‑grade B‑cell lymphoma with MYC and BCL2 rearrangements (DLBCL/HGBL‑MYC/BCL2) is a distinct aggressive entity with poor survival. Conventional R‑CHOP‑like regimens have limited efficacy, and primary refractory disease has a median overall survival of only 7 months. In this case, a 66‑year‑old woman initially diagnosed with follicular lymphoma progressed to DLBCL/HGBL‑MYC/BCL2 while on BR therapy, remained refractory to Pola‑R‑CHP, and subsequently achieved a partial response and long‑term remission after treatment with the CD20×CD3 bispecific antibody glofitamab, supplemented with lenalidomide maintenance. This report demonstrates glofitamab’s potential effectiveness as salvage therapy in this highly refractory subtype.

DLBCL/HGBL‑MYC/BCL2 is associated with a dismal prognosis and limited treatment options. Demonstrating that glofitamab can produce durable responses in primary refractory cases offers a promising therapeutic avenue and informs the design of future clinical trials.

Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.

Original source

Related signals